Cargando…
Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study
BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983439/ https://www.ncbi.nlm.nih.gov/pubmed/36875172 http://dx.doi.org/10.2147/RMHP.S392224 |
_version_ | 1784900546863300608 |
---|---|
author | Qian, Qin Wang, Yu-Zhen Kan, Lian-Di Chen, Jie Wang, Chen Han, Gang Li, Liu-Cheng Lou, Wei-Jian |
author_facet | Qian, Qin Wang, Yu-Zhen Kan, Lian-Di Chen, Jie Wang, Chen Han, Gang Li, Liu-Cheng Lou, Wei-Jian |
author_sort | Qian, Qin |
collection | PubMed |
description | BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China. METHODS: In this study, the demographic, diagnosis, and medication prescription data including the antihypertensive drug types and comorbidities, were analyzed. The antihypertensive drugs use were evaluated according to the Chinese guidelines for hypertension. RESULTS: 1301 prescriptions (number of visits) containing 1880 antihypertensive medical orders were collected. The average number of antihypertensive drugs per prescription was 1.45 (±0.75). The patients aged 16 to 18 (70.18%) accounted for the highest proportion. Kidney diseases (33.28%) were the most common comorbidities. Calcium channel blocker (CCB), angiotensin II receptor blocker (ARB), and β receptor blocker (BB) were the most used antihypertensive drugs. The most frequent monotherapy was CCB, while that of two and three drugs combination were ARB+CCB and ARB+BB+CCB, respectively. Metoprolol (11.44%), nifedipine (10.64%), amlodipine (10.59%), valsartan (6.12%) were the most commonly used antihypertensive drugs. The utilization rate of fixed compound preparations was 7.34%. However, the percentage of recommended antihypertensive drugs was just 14.20%, while the recommended drug combination was 84.93% according to the guidelines. CONCLUSION: For the first time ever we reported the antihypertensive prescription analysis in children in a large area of China. Our data provided new insights into the epidemiological characteristics and drug use in hypertensive children. We found that the guidelines for medication management in hypertensive children were not routinely followed. The wide use of antihypertensive drugs in children and those with weak clinical evidence raised concerns regarding its rational use. The findings could lead to more effective management of hypertension in children. |
format | Online Article Text |
id | pubmed-9983439 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-99834392023-03-04 Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study Qian, Qin Wang, Yu-Zhen Kan, Lian-Di Chen, Jie Wang, Chen Han, Gang Li, Liu-Cheng Lou, Wei-Jian Risk Manag Healthc Policy Original Research BACKGROUND: Pediatric hypertension become an early marker of cardiovascular diseases, but their antihypertensive drug use patterns are rarely known. PURPOSE: To investigate the epidemiological characteristics of pediatric hypertension and the use of antihypertensive drugs in the real world in China. METHODS: In this study, the demographic, diagnosis, and medication prescription data including the antihypertensive drug types and comorbidities, were analyzed. The antihypertensive drugs use were evaluated according to the Chinese guidelines for hypertension. RESULTS: 1301 prescriptions (number of visits) containing 1880 antihypertensive medical orders were collected. The average number of antihypertensive drugs per prescription was 1.45 (±0.75). The patients aged 16 to 18 (70.18%) accounted for the highest proportion. Kidney diseases (33.28%) were the most common comorbidities. Calcium channel blocker (CCB), angiotensin II receptor blocker (ARB), and β receptor blocker (BB) were the most used antihypertensive drugs. The most frequent monotherapy was CCB, while that of two and three drugs combination were ARB+CCB and ARB+BB+CCB, respectively. Metoprolol (11.44%), nifedipine (10.64%), amlodipine (10.59%), valsartan (6.12%) were the most commonly used antihypertensive drugs. The utilization rate of fixed compound preparations was 7.34%. However, the percentage of recommended antihypertensive drugs was just 14.20%, while the recommended drug combination was 84.93% according to the guidelines. CONCLUSION: For the first time ever we reported the antihypertensive prescription analysis in children in a large area of China. Our data provided new insights into the epidemiological characteristics and drug use in hypertensive children. We found that the guidelines for medication management in hypertensive children were not routinely followed. The wide use of antihypertensive drugs in children and those with weak clinical evidence raised concerns regarding its rational use. The findings could lead to more effective management of hypertension in children. Dove 2023-02-27 /pmc/articles/PMC9983439/ /pubmed/36875172 http://dx.doi.org/10.2147/RMHP.S392224 Text en © 2023 Qian et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Qian, Qin Wang, Yu-Zhen Kan, Lian-Di Chen, Jie Wang, Chen Han, Gang Li, Liu-Cheng Lou, Wei-Jian Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title | Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title_full | Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title_fullStr | Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title_full_unstemmed | Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title_short | Real-World Prescribing Patterns for Hypertensive Children in China from 2018 to 2021: A Cross-Sectional Multicenter Study |
title_sort | real-world prescribing patterns for hypertensive children in china from 2018 to 2021: a cross-sectional multicenter study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983439/ https://www.ncbi.nlm.nih.gov/pubmed/36875172 http://dx.doi.org/10.2147/RMHP.S392224 |
work_keys_str_mv | AT qianqin realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT wangyuzhen realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT kanliandi realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT chenjie realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT wangchen realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT hangang realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT liliucheng realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy AT louweijian realworldprescribingpatternsforhypertensivechildreninchinafrom2018to2021acrosssectionalmulticenterstudy |